Text Size

Pediatric Atopic Dermatitis (AD) Internet Survey

This study is currently recruiting participants.
Verified February 2013 by Wake Forest University
Sponsor:
Information provided by (Responsible Party):
Steven R. Feldman, Wake Forest University
ClinicalTrials.gov Identifier:
NCT01385527
First received: June 28, 2011
Last updated: February 21, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.


Condition Intervention
Atopic Dermatitis
 Behavioral: Weekly Internet survey
Drug: Topical Triamcinolone

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Health Services Research
Official Title: Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Wake Forest University:

Primary Outcome Measures:
  • Adherence to topical triamcinolone [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Eczema Area Severity Index [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Investigator's Global Assessment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: June 2011
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Weekly Internet survey plus topical triamcinolone Behavioral: Weekly Internet survey
Parents will complete a weekly online survey about medication use.
Drug: Topical Triamcinolone
Topical triamcinolone to all affected areas once daily
Active Comparator: Topical triamcinolone only (standard-of-care) Drug: Topical Triamcinolone
Topical triamcinolone to all affected areas once daily

  Eligibility

Ages Eligible for Study:   2 Years to 8 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Any child age 2 to 8 with a diagnosis of atopic dermatitis confirmed by a dermatologist, together with the child's parent/guardian. Written consent must be given by parent/guardian.

Exclusion Criteria:

  • Child is less than 2 or greater than 8 years of age.
  • Known allergy or sensitivity to topical triamcinolone in the child.
  • Inability to complete all study-related visits, or inability to complete the Internet survey due to inadequate Internet access.
  • Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. Subjects who are on systemic anti-inflammatory treatments for atopic dermatitis must be on a stable dose for at least 3 months prior to enrollment.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01385527

Contacts
Contact: Susie C Dowd 3367163775 sdowd@wakehealth.edu
Contact: Scott A Davis, MA 3367162702 scdavis@wakehealth.edu

Locations
United States, North Carolina
Wake Forest University Health Sciences Dermatology Recruiting
Winston-Salem, North Carolina, United States, 27104
Contact: Susie C Dowd     336-716-3775     sdowd@wakehealth.edu    
Contact: Scott A Davis, MA     3367162702     scdavis@wakehealth.edu    
Principal Investigator: Steven R Feldman, MD, PhD            
Sponsors and Collaborators
Wake Forest University
Investigators
Principal Investigator: Steven R Feldman, MD, PhD Wake Forest University
  More Information

No publications provided

Responsible Party: Steven R. Feldman, Professor of Dermatology, Wake Forest University
ClinicalTrials.gov Identifier: NCT01385527     History of Changes
Other Study ID Numbers: 00016545
Study First Received: June 28, 2011
Last Updated: February 21, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Triamcinolone hexacetonide
Triamcinolone
Triamcinolone Acetonide
 Triamcinolone diacetate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 21, 2013